MFG
RCKT icon

Mendota Financial Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Mendota Financial Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-45
Closed -$923 – 398
2023
Q3 		$923 Hold
45
– – ﹤0.01% 269
2023
Q2 		$895 Buy
45
+20
+80% +$404 ﹤0.01% 267
2023
Q1 		$397 Sell
25
-20
-44% -$392 ﹤0.01% 294
2022
Q4 		$881 Buy
+45
New +$829 ﹤0.01% 281

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Mendota Financial Group's RCKT Position: Q4 2023 in Review

Mendota Financial Group sold out of Rocket Pharmaceuticals (RCKT) in Q4 2023, closing a stake of 45 shares — an estimated $923 sold.

Mendota Financial Group first reported a position in RCKT in Q4 2022 and held it in 4 quarters. The position peaked at $923 in Q3 2023. 194 funds tracked by Wall St. Rank hold RCKT as of Q4 2023.

  • Mendota Financial Group reported no remaining Rocket Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Mendota Financial Group sold 45 Rocket Pharmaceuticals shares in Q4 2023, an estimated $923.
  • Mendota Financial Group first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Mendota Financial Group's Rocket Pharmaceuticals position peaked at $923 in Q3 2023.
  • 194 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2023.

Based on Mendota Financial Group's 13F filing for Q4 2023, filed 19 Jan 2024.